Solentim are pleased to announce the appointment of Dr Julian Burke as a non-executive Director. A former lecturer in Biochemistry at the University of Sussex, UK, Dr Burke has over 25 years’ experience of executive leadership positions in life science companies. He was Chief Scientific Officer for Genetix Group PLC from 2000 – 2010 until …
Monoclonal antibodies – a recent history Over three decades ago, in 1986, the first monoclonal antibody (mAb) treatment was approved by the United States Food and Drug Administration (US FDA)[1]. Since then, techniques and technologies to identify, engineer and harness mAbs have advanced and therapeutic antibodies have become the primary focus for many drug developers. …
Read more Clonality assurance and the rise of therapeutic monoclonal antibody development
Solentim is happy to announce that its new Cell Line Development platform, the ICON, will launch early 2021. For over a decade, Solentim has provided leading solutions to create, isolate and characterize the highest value cells, accelerating the development of new biological medicines and therapies around the world, in cell line development, vaccine research, stem …
For those delivering advanced therapy medicinal products, the question of assessing and managing cell population heterogeneity presents an ongoing challenge. Solentim and EverCell Bio addressed this topic at a recent webinar during which they discussed the use of induced pluripotent stem cells (iPSCs) and sharing data from EverCell Bio’s iPSC lines when moving into the clinic. …
Read more Is it time for a new standard for the culture of iPSCs?
Solentim is happy to announce that it will be presenting at the 9th Cell Line Development & Engineering Asia conference, taking place 3-5 November 2020. This digitally delivered event brings together the brightest minds, innovators and industry players to uncover novel techniques, optimize workflows, and accelerate CLD for commercial success. Mark Stockdale, Amalgamator of Business and Biology …
As part of the concerted fight against COVID-19, the Vaccine Research Center (VRC) at the National Institute for Allergy and Infectious Diseases at the U.S. National Institutes of Health has invested in two key technology platforms from Solentim: the VIPS™ (Verified In-Situ Plate Seeding) high efficiency single cell seeder, and the Cell Metric® high contrast …
